Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

Given the emergence of NGS in clinical practice, more similar cases will be identified in the coming years. The optimal treatment strategy for this rare group of patients is uncertain and toxicity of combination treatment may have to be considered.